Clinical trial · Observational
Integrated Molecular Analysis of Cancer (IMAC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to identify biomarkers and potentially actionable mutations/ activated molecular pathways and evaluate the impact of molecular profiling information on patients with cancer. The hypothesis of the study are: * Analysis of tumour samples will allow us to identify novel and/or actionable molecular changes that may drive therapeutic strategies for the management of cancers. * Molecular profiling will improve the outcome of novel targeted-agent treatment in clinical trials * Molecular profiling of paired samples (primary/recurrent and primary/metastatic) will provide new insights into mechanisms underlying drug resistance and metastasis in cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Integrated Molecular Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All cancer
- interventionNames
- Other: Integrated Molecular Analysis
Primary outcomes (3)
- measure
- 1. Characterization of identified biomarkers and potentially actionable mutations/ activated molecular pathways
- timeFrame
- 2 years
- description
- By identifying biomarkers and actionable mutations/molecular pathways in patients and characterizing them, we can evaluate the impact of molecular profiling information on patients with cancer. The spectrum and development of molecularly targeted agents is rapidly expanding, and it is increasingly likely that the future of cancer management will require the molecular and histological subtype of one's tumor to be defined in order to decide on the most appropriate treatment strategy.
- measure
- To compare progression free survival (PFS) on matched therapy vs non-matched therapy in cancer patients enrolled into molecular targeted therapy/ biomarker-driven clinical trials.
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histological confirmation of cancers who are candidates for systemic therapy, including molecular-targeted therapy/ biomarker-driven clinical trials. 2. Patients must be ≥ 21 years old. 3. All patients must have signed and dated an informed consent form. 4. All patients must have sufficient tumour tissue for molecular profiling Exclusion Criteria: Unable to provide informed consent
References
Publications (2)
- BACKGROUNDKola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. No abstract available. PMID 15286737
- BACKGROUNDStewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009 Jan 20;27(3):328-33. doi: 10.1200/JCO.2008.18.9621. Epub 2008 Dec 8. No abstract available. PMID 19064964